# reload+after+2024-01-23 14:47:50.514437
address1§260 Sheridan Avenue
address2§Suite 400
city§Palo Alto
state§CA
zip§94306
country§United States
phone§650 800 6676
website§https://vincerx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
fullTimeEmployees§41
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Ahmed M. Hamdy M.D.', 'age': 58, 'title': 'Founder, Chairman & CEO', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 609844, 'exercisedValue': 0, 'unexercisedValue': 500}, {'maxAge': 1, 'name': 'Dr. Raquel E. Izumi Ph.D.', 'age': 53, 'title': 'Founder, President, COO, Secretary & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 551660, 'exercisedValue': 0, 'unexercisedValue': 500}, {'maxAge': 1, 'name': 'Mr. Alexander A. Seelenberger M.B.A.', 'age': 44, 'title': 'Chief Financial Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 458029, 'exercisedValue': 0, 'unexercisedValue': 467}, {'maxAge': 1, 'name': 'Mr. Tom C. Thomas J.D.', 'age': 64, 'title': 'Founder, General Counsel & Chief Legal Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 444142, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John C. Byrd M.D.', 'title': 'Founder & Chairman of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hans-Georg  Lerchen Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Gabriela  Jairala', 'title': 'Sr Executive Director of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen  Quarford', 'title': 'Vice President of Quality Operations & Compliance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Melissa  Merrick SPHR', 'title': 'Senior Director of People & Culture and Head of Human Resource', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Beatrix  Stelte-Ludwig Ph.D.', 'title': 'Executive Chief Development Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.096
currency§USD
dateShortInterest§1702598400
forwardEps§-0.58
exchange§NCM
quoteType§EQUITY
shortName§Vincerx Pharma, Inc.
longName§Vincerx Pharma, Inc.
firstTradeDateEpochUtc§1590586200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§46789548-9ff1-3829-9a39-73e43f85b2b7
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§4.0
targetMeanPrice§7.0
targetMedianPrice§7.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§2.471
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
